French Brain Tumor DataBase: 5-Year Histological Results on 25???756 Cases, Brain Pathology, vol.8, issue.7, pp.633-677, 2004. ,
DOI : 10.1215/S1522851705000268
Epidemiology and molecular pathology of glioma, Nature Clinical Practice Neurology, vol.14, issue.9, pp.494-503, 2006. ,
DOI : 10.3171/foc.2005.19.5.6
Gliomes de grade II. EMC -Neurol, 2008. ,
DOI : 10.1016/s0246-0378(08)46100-6
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, 2005. ,
Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force, European Journal of Neurology, vol.27, issue.9, pp.1124-1157, 2010. ,
DOI : 10.1200/JCO.2008.20.5765
on behalf of the ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol ESMO, 2014. ,
Imagerie c??r??brale des gliomes : diagnostic et suivi conventionnels, Journal de Radiologie, vol.87, issue.6, pp.779-91, 2006. ,
DOI : 10.1016/S0221-0363(06)74087-2
Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro- Oncol, pp.176-82, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00349509
Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors, Neurosurgery, vol.56, issue.5, pp.919-945, 2005. ,
Optimization of semiquantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas, J Neurol Sci Jul, vol.15246, issue.12, pp.85-94, 2006. ,
Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma, Journal of Nuclear Medicine, vol.54, issue.12, pp.2046-54, 2013. ,
DOI : 10.2967/jnumed.113.123836
Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas, Journal of Nuclear Medicine, vol.51, issue.10, pp.1532-1540, 2010. ,
DOI : 10.2967/jnumed.110.078592
Evaluation of Quantitative Criteria for Glioma Grading With Static and Dynamic 18F-FDopa PET/CT, Clinical Nuclear Medicine, vol.38, issue.2, pp.81-88, 2013. ,
DOI : 10.1097/RLU.0b013e318279fd5a
18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.34, issue.7, pp.1025-1060 ,
DOI : 10.1097/RLU.0b013e3181becfe0
Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms, Journal of the Neurological Sciences, vol.136, issue.1-2, pp.169-73, 1996. ,
DOI : 10.1016/0022-510X(95)00316-T
Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-l-DOPA11Abbreviations: AAAD, aromatic l-amino acid decarboxylase; BBB, blood-brain barrier; BUI, brain uptake index; carbidopa, l-??-hydrazino-??-methyl-??-(3,4-dihydroxyphenyl)propionic acid; l-DOPA, l-3,4-dihydroxyphenylalanine; FDA, 6-fluorodopamine; [18F]FDOPA, 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine; 4-[18F]FMT, 4-[18F]fluoro-l-meta-tyrosine; 6-[18F]FMT, 6-[18F]fluoro-l-meta-tyrosine; MeAIB, ??-(methylamino)isobutyric acid; MPTP, 1-methyl-1,2,3,6-tetrahydropyridine; PD, Parkinson???s disease; PET, positron emission tomography; and PLP, pyridoxal phosphate., Biochemical Pharmacology, vol.62, issue.10, pp.1409-1424, 2001. ,
DOI : 10.1016/S0006-2952(01)00787-0
Tumor Cell Metabolism Imaging, Journal of Nuclear Medicine, vol.49, issue.Suppl_2, pp.43-63, 2008. ,
DOI : 10.2967/jnumed.107.045930
URL : http://jnm.snmjournals.org/content/49/Suppl_2/43S.full.pdf
3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro, J Nucl Med Off Publ Soc Nucl Med, vol.45, issue.12, pp.2116-2138, 2004. ,
Enhanced Tumor Growth Elicited by L-Type Amino Acid Transporter 1 in Human Malignant Glioma Cells, Neurosurgery, vol.275, issue.2, pp.493-503, 2008. ,
DOI : 10.1074/jbc.275.7.5059
F-Dopa as an amino acid tracer to detect brain tumors, J Nucl, 1996. ,
18F- FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.6, pp.904-915, 2006. ,
Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas, Clinical Nuclear Medicine, vol.34, issue.12, pp.878-83, 2009. ,
DOI : 10.1097/RLU.0b013e3181becfe0
18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience, European Journal of Radiology, vol.71, issue.2, pp.242-250, 2009. ,
DOI : 10.1016/j.ejrad.2008.04.018
18F-FDOPA kinetics in brain tumors J Nucl Med Off Publ Soc Nucl Med, 96 28. afssaps. RAPPORT PUBLIC D'EVALUATION SCIENTIFIQUE discussion scientifique IASOdopa, Solution injectable FDOPA-(18F) (6-fluoro-(18F)-L-3, pp.1651-614, 2007. ,
Impact of 3,4-Dihydroxy-6-18F-Fluoro-L-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective, Journal of Nuclear Medicine, vol.53, issue.3, pp.393-401, 2012. ,
DOI : 10.2967/jnumed.111.095711
R??f??rentiel gliomes diffus de l???adulte de grade OMS II,??III et IV??: anatomie pathologique et biologie, Annales de Pathologie, vol.32, issue.5, 2012. ,
DOI : 10.1016/j.annpat.2012.09.228
Advances in Evaluation of Primary Brain Tumors, Seminars in Nuclear Medicine, vol.38, issue.4, pp.240-50, 2008. ,
DOI : 10.1053/j.semnuclmed.2008.02.005
Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma., Journal of Clinical Oncology, vol.12, issue.9, pp.1886-1895, 1994. ,
DOI : 10.1200/JCO.1994.12.9.1886
Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium, Cancer, vol.16, issue.2-3, pp.1953-68, 2008. ,
DOI : 10.1212/01.WNL.0000129533.26544.BF
Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System, Journal of Neurosurgery, vol.16, issue.2, pp.203-213, 2009. ,
DOI : 10.1016/0360-3016(90)90397-3
A Comparison of the Predictive Power for Survival in Gliomas Provided by MIB-1, Bromodeoxyuridine and Proliferating Cell Nuclear Antigen with Histopathologic and Clinical Parameters, Journal of Neuropathology and Experimental Neurology, vol.56, issue.7, pp.798-805, 1997. ,
DOI : 10.1097/00005072-199756070-00006
Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer, pp.373-80, 1996. ,
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004, Neuro-Oncology, vol.71, issue.9311, pp.725-760, 2004. ,
DOI : 10.1016/S0140-6736(02)08091-1
MR imaging correlates of survival in patients with high-grade gliomas, AJNR Am J Neuroradiol, 2005. ,
Glioblastomes??: facteurs pronostiques cliniques, radiologiques et biologiques, Neurochirurgie, vol.56, issue.6, pp.467-76, 2010. ,
DOI : 10.1016/j.neuchi.2010.07.008
Predictive and prognostic factors for gliomas, Expert Review of Anticancer Therapy, vol.130, issue.5, pp.781-790, 2011. ,
DOI : 10.1016/j.ccr.2006.11.021
Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, vol.123, issue.7216, pp.1061-1069, 2008. ,
DOI : 10.2174/187152008784220276
Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer, Oncogene, vol.20, issue.1, pp.1-8, 2004. ,
DOI : 10.1002/mc.10094
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005. ,
DOI : 10.1056/NEJMoa043330
Image guided surgery for the resection of brain tumours, Cochrane Database of Systematic Reviews, vol.115, issue.2, p.9685, 2014. ,
DOI : 10.3171/2011.3.JNS101333
Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity, The Lancet Neurology, vol.4, issue.8, pp.476-86, 2005. ,
DOI : 10.1016/S1474-4422(05)70140-X
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-72, 2010. ,
DOI : 10.1200/JCO.2009.26.3541
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy, British Journal of Cancer, vol.17, issue.4 ,
DOI : 10.1200/JCO.1999.17.9.2762
A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma, Journal of Neurosurgery, vol.56, issue.6, pp.1170-1174, 2003. ,
DOI : 10.1177/088307389400900317
Quantitative Morphological Magnetic Resonance Imaging Follow-up of Low-Grade Glioma, Neurosurgery, vol.29, issue.1, pp.729-769, 2012. ,
DOI : 10.1109/TMI.2009.2026413
Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases, Journal of Neurosurgery, vol.19, issue.4, 2013. ,
DOI : 10.1016/S1474-4422(03)00434-4
The " onco-functional balance " in surgery for diffuse lowgrade glioma: integrating the extent of resection with quality of life, Acta Neurochir ,
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, Feb Lancet, vol.28155366, issue.69490, pp.951-958, 2005. ,
Current treatment of low grade gliomas. Memo -Mag Eur Med Oncol, pp.223-230, 2012. ,
Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution, Phys Med Biol, 1999. ,
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.12, pp.2103-2113, 2009. ,
DOI : 10.1212/WNL.57.11.2083
Brain tumour imaging with PET: a comparison between ,
11C-Methionine PET for Grading and Prognostication in Gliomas: A Comparison Study with 18F-FDG PET and Contrast Enhancement on MRI, Journal of Nuclear Medicine, vol.53, issue.11, pp.1709-1724, 2012. ,
DOI : 10.2967/jnumed.111.102533
EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.11, pp.1374-80, 2006. ,
DOI : 10.1007/s00259-006-0206-3
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, Journal of Nuclear Medicine, vol.50, issue.Suppl_1, pp.122-150, 2009. ,
DOI : 10.2967/jnumed.108.057307
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab, Neuro-Oncology, vol.62, issue.10, pp.1079-89, 2012. ,
DOI : 10.1016/S0006-2952(01)00787-0
Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients, Neuro-Oncology, vol.40, issue.18, pp.603-612, 2014. ,
DOI : 10.1007/s00259-013-2384-0
11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: A stereotactic image-histology comparison, NeuroImage, vol.49, issue.4, pp.2977-82, 2010. ,
DOI : 10.1016/j.neuroimage.2009.11.024
Proliferationdependent changes in amino acid transport and glucose metabolism in glioma cell lines Available from, Eur J Nucl Med Mol Imaging [Internet], vol.31, issue.9, pp.259-263, 2004. ,
improve survival: the standard treatment is surgery In cases of incomplete resection or aggressive type of tumor, chemotherapy and radiotherapy are options. Post-operative radiotherapy is discussed depending on prognostic factors (17) Chemotherapy has less side effects regarding cognitive toxicity and neuroplasticity than radiotherapy (18) The aim is to prolong survival while preserving quality of life and to control tumoral mass-related symptoms. On the contrary, the treatment of HGG is based on primary surgery as large as feasible and on adjuvant radiochemotherapy or continuous chemotherapy (18) So it is of crucial importance to detect malignant transformation and optimal time for commencing adjuvant treatments ,
French Brain Tumor DataBase: 5-Year Histological Results on 25???756 Cases, Brain Pathology, vol.8, issue.7, pp.633-677, 2004. ,
DOI : 10.1215/S1522851705000268
Epidemiology and molecular pathology of glioma, Nature Clinical Practice Neurology, vol.14, issue.9, pp.494-503, 2006. ,
DOI : 10.3171/foc.2005.19.5.6
The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica, vol.64, issue.2, pp.97-109, 2007. ,
DOI : 10.1093/jnen/60.9.863
Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases, Journal of Neurosurgery, vol.19, issue.4, 2013. ,
DOI : 10.1016/S1474-4422(03)00434-4
Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force, European Journal of Neurology, vol.27, issue.9, pp.1124-1157, 2010. ,
DOI : 10.1200/JCO.2008.20.5765
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004, Neuro-Oncology, vol.71, issue.9311, pp.725-760, 2004. ,
DOI : 10.1016/S0140-6736(02)08091-1
Predictive and prognostic factors for gliomas, Expert Review of Anticancer Therapy, vol.130, issue.5, pp.781-790, 2011. ,
DOI : 10.1016/j.ccr.2006.11.021
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402, Journal of Clinical Oncology, vol.31, issue.3, pp.337-380, 2013. ,
DOI : 10.1200/JCO.2012.43.2674
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-72, 2010. ,
DOI : 10.1200/JCO.2009.26.3541
Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study, American Journal of Neuroradiology, vol.239, issue.3, pp.1505-1515, 2008. ,
DOI : 10.1148/radiol.2393042031
F-Dopa as an amino acid tracer to detect brain tumors, J Nucl, 1996. ,
Tumor Cell Metabolism Imaging, Journal of Nuclear Medicine, vol.49, issue.Suppl_2, pp.43-63, 2008. ,
DOI : 10.2967/jnumed.107.045930
URL : http://jnm.snmjournals.org/content/49/Suppl_2/43S.full.pdf
Proliferationdependent changes in amino acid transport and glucose metabolism in glioma cell lines ,
Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-l-DOPA11Abbreviations: AAAD, aromatic l-amino acid decarboxylase; BBB, blood-brain barrier; BUI, brain uptake index; carbidopa, l-??-hydrazino-??-methyl-??-(3,4-dihydroxyphenyl)propionic acid; l-DOPA, l-3,4-dihydroxyphenylalanine; FDA, 6-fluorodopamine; [18F]FDOPA, 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine; 4-[18F]FMT, 4-[18F]fluoro-l-meta-tyrosine; 6-[18F]FMT, 6-[18F]fluoro-l-meta-tyrosine; MeAIB, ??-(methylamino)isobutyric acid; MPTP, 1-methyl-1,2,3,6-tetrahydropyridine; PD, Parkinson???s disease; PET, positron emission tomography; and PLP, pyridoxal phosphate., Biochemical Pharmacology, vol.62, issue.10, pp.1409-1424, 2001. ,
DOI : 10.1016/S0006-2952(01)00787-0
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.6, pp.904-915, 2006. ,
Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas, Journal of Nuclear Medicine, vol.51, issue.10, pp.1532-1540, 2010. ,
DOI : 10.2967/jnumed.110.078592
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, The Lancet, vol.366, issue.9490, pp.985-90, 2005. ,
DOI : 10.1016/S0140-6736(05)67070-5
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005. ,
DOI : 10.1056/NEJMoa043330
Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro-Oncol, pp.176-82, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00349509
Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma., Journal of Clinical Oncology, vol.12, issue.9, pp.1886-1895, 1994. ,
DOI : 10.1200/JCO.1994.12.9.1886
Evaluation of Quantitative Criteria for Glioma Grading With Static and Dynamic 18F-FDopa PET/CT, Clinical Nuclear Medicine, vol.38, issue.2, pp.81-88, 2013. ,
DOI : 10.1097/RLU.0b013e318279fd5a
18F-FDOPA Kinetics in Brain Tumors, Journal of Nuclear Medicine, vol.48, issue.10, pp.1651-61, 2007. ,
DOI : 10.2967/jnumed.106.039321
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab, Neuro-Oncology, vol.62, issue.10, 2012. ,
DOI : 10.1016/S0006-2952(01)00787-0
11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: A stereotactic image-histology comparison, NeuroImage, vol.49, issue.4, pp.2977-82, 2010. ,
DOI : 10.1016/j.neuroimage.2009.11.024
A recovery coefficient method for partial volume correction of PET images, Annals of Nuclear Medicine, vol.45, issue.4, 2009. ,
DOI : 10.1148/radiology.188.2.8327702